STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.